Document is current
Any future updates will be listed below
-
Authors
Ozga, Michael
Nicolet, Deedra
Mrózek, Krzysztof http://orcid.org/0000-0002-1408-5063
Yilmaz, Ayse S.
Kohlschmidt, Jessica
Larkin, Karilyn T.
Blachly, James S. http://orcid.org/0000-0002-4275-5562
Oakes, Christopher C.
Buss, Jill
Walker, Christopher J.
Orwick, Shelley http://orcid.org/0000-0002-4537-1409
Jurinovic, Vindi
Rothenberg-Thurley, Maja
Dufour, Annika
Schneider, Stephanie
Sauerland, Maria Cristina
Görlich, Dennis http://orcid.org/0000-0002-2574-9419
Krug, Utz
Berdel, Wolfgang E.
Woermann, Bernhard J.
Hiddemann, Wolfgang
Braess, Jan
Subklewe, Marion http://orcid.org/0000-0001-9154-9469
Spiekermann, Karsten http://orcid.org/0000-0002-5139-4957
Carroll, Andrew J.
Blum, William G.
Powell, Bayard L.
Kolitz, Jonathan E.
Moore, Joseph O.
Mayer, Robert J.
Larson, Richard A. http://orcid.org/0000-0001-9168-3203
Uy, Geoffrey L.
Stock, Wendy
Metzeler, Klaus H.
Grimes, H. Leighton http://orcid.org/0000-0001-8162-6758
Byrd, John C.
Salomonis, Nathan
Herold, Tobias http://orcid.org/0000-0002-9615-9432
Mims, Alice S. http://orcid.org/0000-0002-8971-2199
Eisfeld, Ann-Kathrin http://orcid.org/0000-0001-6442-1419
- License Information
-
More Information
Article History
Received: 24 June 2023
Revised: 25 September 2023
Accepted: 9 October 2023
First Online: 28 November 2023
Competing interests
: CJW is a consultant for Vigeo Therapeutics and employed at Karyopharm Therapeutics; and has ownership interest in Karyopharm Therapeutics and Bristol-Myers Squibb Co. JSB is a consultant/advisory board member for AbbVie, AstraZeneca, INNATE, KITE. BLP received honoraria from Jazz Pharmaceuticals, Novartis, and Pfizer. JEK has received honoraria from Gilead, Magellan, and Novartis; consulting fees from Gilead, Magellan, Novartis, Pharmacyclics, and Seattle Genetics; institutional research funding from Boehringer Ingelheim, Cantex, Erytech, and Millennium; and travel support from Gilead, Novartis, and Seattle Genetics. JCB has a consultancy/advisory role with Syndax, Novartis, Vincera; research funding from Pharmacyclics LLC, an AbbVie Company, Genentech, Janssen, Acerta; ownership for Vincera. A-KE has a current employment of her spouse at Karyopharm Therapeutics. The other authors declare no competing financial interests.
